Glewis S, Fagery M, Lingaratnam S, Harris S, Georgiou C, Underhill C, Warren M, Campbell R, Martin JH, Tie J, IJzerman M, Alexander M, Michael M. Cost-Effectiveness of Pre-emptive DPYD Genotyping Compared to Standard of Care Among Patients Receiving Fluoropyrimidine-Based Anti-cancer Treatment in Australia. Clinical Drug Investigation. 2025;45(12):10.1007/s40261-025-01489-w
Salem ME, Puccini A, Mauer E, André T, George TJ, Tabernero J, Sinicrope FA, Tie J, Kopetz S, Van Cutsem E, Lonardi S, Overman MJ, Foureau D. Impact of RAS/BRAF V600E mutations on the tumor immune microenvironment in mismatch repair deficient /microsatellite instability colorectal cancers.Clinical Cancer Research. 2025;:10.1158/1078-0432.ccr-25-2160
McLachlan S-A, Singh M, Hayes T, Lundy J, Wong ZW, Chong G, Saqib A, Steel S, Aghmesheh M, Begbie S, Roohullah A, Beale P, Ng W, Diakos C, Srivastav R, Rai S, Wong M, Karikios D, Barnett M, Lum C, Underhill C, Poursoltan P, Karki B, Karapetis C, Price T, Khattak A, Wuttke M, Karanth N, Jeffery M, Yelamanchili R, Batra A, Roitman D, Gotfrit J, Mussawar I, Kassam S, Goffin J, Rask S, Hubay S, Chen E, Samimi S, Martel S, Zurawska U, Wong R, Sideris L, Tang P, McGhie J, Arif S, Ahmed S, Michael J, Shim K, Babak S, Armstrong D, Burkes R, Kavan P. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial. Nature Medicine. 2025;:10.1038/s41591-025-04030-w
Wonglhow J, Wong H-L, Michael M, Heriot A, Guerra G, Mitchell C, Tie J. Survival Outcomes and Prognostic Factors in Metastatic Unresectable Appendiceal Adenocarcinoma Treated with Palliative Systemic Chemotherapy: A 10-Year Retrospective Analysis from Australia. Cancers. 2025;17(20):10.3390/cancers17203297
Tie J. PSY4-2 Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer. Annals of Oncology. 2025;36:10.1016/j.annonc.2025.08.038
Zaman FY, Orchard SG, Polekhina G, Gibbs P, Bernstein WB, Macrae F, Tie J, Millar J, Gately L, Rodríguez LM, van Londen GJ, Mar V, Hiscutt E, Adler N, Kent A, Ong WL, Haydon A, Warner E, Chan AT, Zalcberg J. Association of non-steroidal anti-inflammatory medications and aspirin with colorectal cancer incidence in older adults. Journal of the National Cancer Institute. 2025;117(9):10.1093/jnci/djaf145
Hitchen N, Wong H-L, Wong R, Shapiro J, Burge M, Nott L, Lee B, Lim SH, Wong SF, Caird S, Wong V, Rainey N, Khattak A, Mandaliya H, Hayes T, Torres J, Jalali A, Campbell A, Gibbs P, Tie J. Real-world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: the COALA project. ESMO Real World Data and Digital Oncology. 2025;9:10.1016/j.esmorw.2025.100178
Hitchen N, Lee MMW, Kosmider S, Wong R, Wong H, Hong W, Chapman M, Debrincat M, Stirzaker R, Gibbs P, Gao Y, Tie J, Hung T. 1772eP Clinical performance of a blood-only, targeted methylation circulating tumor DNA (ctDNA) assay for minimal residual disease (MRD) detection in colorectal cancer (CRC). Annals of Oncology. 2025;36:10.1016/j.annonc.2025.08.2400
Raghav K, Siena S, Takashima A, Kato K, van den Eynde M, Pietrantonio F, Komatsu Y, Kawakami H, Peeters M, André T, Lonardi S, Yamaguchi K, Tie J, Castro MCG, Strickler JH, Barrios D, Goodman E, Kamio T, Abe K, Yoshino T. 737MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic colorectal cancer (mCRC): Final analysis of DESTINY-CRC02, a randomized, phase II trial. Annals of Oncology. 2025;36:10.1016/j.annonc.2025.08.1311
Morris V, Fernandez EE, Tie J, Kopetz S, Van Cutsem E, Wasan HS, Lonardi S, Eng C, Yoshino T, Kim TW, Shen L, Chen Z, Raphael M, Marques EP, Vollebergh M, Usari T, Beyzarov E, Olu K, Zhang X, Tabernero J. 809P Safety profile associated with first-line (1L) encorafenib plus cetuximab (EC) ± mFOLFOX6 and chemotherapy (chemo) ± bevacizumab (bev) in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) (BREAKWATER). Annals of Oncology. 2025;36:10.1016/j.annonc.2025.08.1382
